Page 54 - SaxoCell Annual Report22/23

CLINICS

SaxoCellCLINICS was founded to provide resources and services for innovative research projects
with clinical relevance in the SaxoCell cluster in the best possible way. The platform acts both as a
clinical contact for project partners and as an interface between research institutions, authorities,
industry and other platforms in the cluster.

Project lead: Uwe Platzbecker & Silke Gloaguen

Partners: University Hospital Leipzig, University Hospital Dresden, Center for Clinical Studies
Leipzig (ZKS), Coordination Center Clinical Studies Dresden (KKS)

The specific objectives of the platform are defined as follows:

1. Establishment of a central coordination structure for clinical and regulatory aspects in the field

of gene and cell therapy in the SaxoCell cluster.
2. Optimization of translation of phase 1-3 clinical trials in the field of cell and gene therapy.
3. Consulting and establishment of networks.
4. Establishment of a registry and harmonization of biobanking (SaxoCell-Bio) for cell and gene
therapies in Saxony.

The SaxoCellCLINICS platform has already made important progress. Fixed contact persons with
clear tasks have been appointed, including Uwe Platzbecker as scientific director, who is primarily
responsible for clinical-scientific issues and study designs. Silke Gloaguen leads the coordinative
activities of the platform, while Janine Kirchberg is an important link between specific cluster
projects and the platform.

SaxoCellClinics platform staff regularly attend cluster meetings and are available as contacts for
projects and working groups in the cluster. The platform focuses on training and advising partners
in clinical trials as well as providing support in later preclinical phases. It works closely with the
Paul Ehrlich Institute (PEI), the state directorate and other authorities.

49